Back
Cartesian Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
RNAC
Sponsored
Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term
See if stocks could soar as much as 1,000% if history repeats itself.
Buy
70
RNAC
Cartesian Therapeutics
Last Price:
16.97
Seasonality Move:
10.73%
7 Day Trial
ALL ACCESS PASS
$
7
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More HereCartesian Therapeutics Price Quote
$16.97
+0.04 (+0.24%)
(Updated: November 13, 2024 at 5:55 PM ET)
Cartesian Therapeutics Key Stats
Buy
70
Cartesian Therapeutics (RNAC)
is a Buy
Day range:
$16.57 - $19.62
52-week range:
$11.67 - $42.60
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.63
P/B ratio:
0%
Volume:
85.8K
Avg. volume:
111.2K
1-year change:
-41.08%
Market cap:
$404.6M
Revenue:
$26M
EPS:
$-53.46
How Much Does Cartesian Therapeutics Make?
-
How Much Are Cartesian Therapeutics's Sales Annually?
RNAC Revenues are $26M -
How Much Profit Does Cartesian Therapeutics's Make A Year?
RNAC net income is -$219.7M
Is Cartesian Therapeutics Growing As A Company?
-
What Is Cartesian Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 5.37% -
What Is Cartesian Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Cartesian Therapeutics Stock Price Performance
-
Did Cartesian Therapeutics Stock Go Up Last Month?
Cartesian Therapeutics share price went down by -23.6% last month -
Did RNAC's Share Price Rise Over The Last Year?
RNAC share price fell by -41.08% over the past 1 year
What Is Cartesian Therapeutics 52-Week High & Low?
-
What Is Cartesian Therapeutics’s 52-Week High Share Price?
Cartesian Therapeutics has traded as high as $42.60 over the past 52 weeks -
What Is Cartesian Therapeutics’s 52-Week Low Share Price?
Cartesian Therapeutics has traded as low as $11.67 over the past 52 weeks
Cartesian Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Cartesian Therapeutics?
-
How Much Debt Does Cartesian Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Cartesian Therapeutics Have?
Cash and short term investments quarterly total is $87.2M -
What Is Cartesian Therapeutics’s Book Value Per Share?
Book value per share is -5.69
Is Cartesian Therapeutics Cash Flow Positive?
-
What Is RNAC Cash Flow From Operations?
Cash flow from operations (TTM) is -$62.9M -
What Is Cartesian Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $32.4M -
What Is Cartesian Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $4.3M
Cartesian Therapeutics Return On Invested Capital
Data Unavailable
Cartesian Therapeutics Earnings Date & Stock Price
-
What Is Cartesian Therapeutics's Stock Price Today?
A single share of RNAC can be purchased today for 16.93 -
What Is Cartesian Therapeutics’s Stock Symbol?
Cartesian Therapeutics trades on the nasdaq under the ticker symbol: RNAC -
When Is Cartesian Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Cartesian Therapeutics is scheduled on March 7, 2025 -
When Is RNAC's next ex-dividend date?
Cartesian Therapeutics's next ex-dividend date is November 14, 2024 -
How To Buy Cartesian Therapeutics Stock?
You can buy Cartesian Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Cartesian Therapeutics Competitors
-
Who Are Cartesian Therapeutics's Competitors?
Below is a list of companies who compete with Cartesian Therapeutics or are related in some way:
Cartesian Therapeutics Dividend Yield
-
What Is RNAC Dividend Yield?
Cartesian Therapeutics’s dividend yield currently is 0% -
What Is Cartesian Therapeutics’s Payout Ratio?
Cartesian Therapeutics’s payout ratio is 0% -
When Did Cartesian Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 14, 2024 -
What Is Cartesian Therapeutics’s Dividend Per Share?
Cartesian Therapeutics pays a dividend of $0.00 per share
Cartesian Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 23.09% |
Revenue: | 537.17% | -78.89% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 40.25 |
Upside from Last Price: | 137.74% |